Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Other solid neoplasm 1

Conditions

Carcinoma, Non-Small-Cell Lung 150Lung Neoplasms 58Pancreatic Neoplasms 34Neoplasms 20Neoplasm Metastasis 15Breast Neoplasms 15Adenocarcinoma of Lung 15Brain Neoplasms 14Adenocarcinoma, Bronchiolo-Alveolar 13Glioblastoma 12Non-Squamous Non-Small Cell Lung Cancer 11Head and Neck Neoplasms 11Gliosarcoma 11Squamous Cell Carcinoma of Head and Neck 10Carcinoma, Hepatocellular 10Colorectal Neoplasms 8Carcinoma, Renal Cell 8Esophageal Neoplasms 6Urinary Bladder Neoplasms 5Gallbladder Neoplasms 5Colonic Neoplasms 5Central Nervous System Neoplasms 5Carcinoma, Squamous Cell 5Adenocarcinoma 5Rectal Neoplasms 4Prostatic Neoplasms 4Ovarian Neoplasms 4Liver Neoplasms 4Kidney Neoplasms 4Fallopian Tube Neoplasms 4

Interventions

Pemetrexed 10Cisplatin 9Gemcitabine 8Nivolumab 5Ipilimumab 4Carboplatin 4niraparib 3durvalumab 3Vinorelbine 3Bevacizumab 3tremelimumab 2pembrolizumab 2olaparib 2anetumab ravtansine 2Radiotherapy, Intensity-Modulated 2Oxaliplatin 2Imatinib Mesylate 2Hyperthermic Intraperitoneal Chemotherapy 2Fluorodeoxyglucose F18 2Cytoreduction Surgical Procedures 2vandetanib 1tislelizumab 1tazemetostat 1spartalizumab 1sargramostim 1ribociclib 1fludarabine phosphate 1fludarabine 1dostarlimab 1defactinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Mesothelioma × Erlotinib Hydrochloride × Clear all
NCT00137826 2011-12-26

Bevacizumab (Avastin) and Erlotinib (Tarceva) in Previously Treated Mesothelioma

Dana-Farber Cancer Institute

Phase 2 Completed
37 enrolled
Other solid neoplasmThoracic

Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡